Search research articles
Contact Us
Filters
Showing results (91-100 of 131) with videos related to
Page
of 14
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
November 7, 2016
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors
Yong-Jin Wu, Jason Guernon, Ramkumar Rajamani, et al.
The Journal of Biological Chemistry
|
October 13, 2007
Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology
Lawrence G Iben, Richard E Olson, Lynn A Balanda, et al.
Clinical Pharmacokinetics
|
September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Randy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.
Plos One
|
October 12, 2013
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease
Jere E Meredith, Sethu Sankaranarayanan, Valerie Guss, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 1, 2015
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice
Deepak R Thakker, Sethu Sankaranarayanan, Marcy R Weatherspoon, et al.
British Journal of Clinical Pharmacology
|
May 24, 2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Journal of Biomolecular Screening
|
March 17, 2011
A high-throughput screen for receptor protein tyrosine phosphatase-gamma selective inhibitors
Kingsley K Appiah, Walter A Kostich, Samuel W Gerritz, et al.
Cell Reports
|
July 7, 2017
Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes
Laura T Haas, Santiago V Salazar, Levi M Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 21, 2007
Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice
Margi E Goldstein, Yang Cao, Tracey Fiedler, et al.
Clinical Therapeutics
|
March 3, 2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 131) with videos related to
Sort By:
Page
of 14
Bioorganic & Medicinal Chemistry Letters
|
November 7, 2016
Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors
Yong-Jin Wu, Jason Guernon, Ramkumar Rajamani, et al.
The Journal of Biological Chemistry
|
October 13, 2007
Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology
Lawrence G Iben, Richard E Olson, Lynn A Balanda, et al.
Clinical Pharmacokinetics
|
September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Randy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.
Plos One
|
October 12, 2013
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease
Jere E Meredith, Sethu Sankaranarayanan, Valerie Guss, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 1, 2015
Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice
Deepak R Thakker, Sethu Sankaranarayanan, Marcy R Weatherspoon, et al.
British Journal of Clinical Pharmacology
|
May 24, 2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Journal of Biomolecular Screening
|
March 17, 2011
A high-throughput screen for receptor protein tyrosine phosphatase-gamma selective inhibitors
Kingsley K Appiah, Walter A Kostich, Samuel W Gerritz, et al.
Cell Reports
|
July 7, 2017
Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes
Laura T Haas, Santiago V Salazar, Levi M Smith, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 21, 2007
Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice
Margi E Goldstein, Yang Cao, Tracey Fiedler, et al.
Clinical Therapeutics
|
March 3, 2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers
Gary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Page
of 14